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by initial treatment strategy (MED, PCI, CABG) using SF-36 physical function, health util- 
ity and Seattle angina questionnaire. Linear modeling to predict 1 year physical function 
(SF-36 PF) included pt characteristics and treatment strategy. 
Results: PCI was the initial treatment strategy in 41%, CABG 22% and MED 37% I” eld- 
erly CAD pts. Survival at 1 yr was highest among pts undergolng CABG (60% CABG, 
72% PCI, 50% MED). Pts undergoing CABG also had less angina, higher health utility 
rating, and better physical functioning at 1 yr than those treated with either PCI or MED 
(Table). CABG remained a significant predlctor (p=O.OOl) of higher 1 yr physical function 
(PF) even after adjusting for baseline PF. age, gender, education, prior MI, DM, PVD, 
EF, CAD severity and other predictors. In contrast, pts undergoing PCI had a non-signifi- 
cant trend toward better physical functioning at 1 year. 
Conclusions: After adjusting for potential confounders, CABG still affords elderly pts 
significantly better angma relief and funchonal outcomes at 1 year than either MED or 
IO:45 a.m. 
888-2 The Relationship Between B-Type Natriuretic Peptide, 
Heart Structure, and Function in 4,300 Patients With 
Heart Failure Enrolled to Val-HeFT 
Roberto Latini, Serge Masson, Lidia Staszewsky, Aldo P. Maggioni, Albert0 Volpi, 
Simona Barlera, lnderjit S. Anand, Allen Hester, Maylene Wang, Jay N. Cohn, on the 
behalf of Val-HeFT Investigators, lstituto Mario Negri, Milan, Italy. Uwersity of 
Minnesota, Minneapolis, MN 
Background: Although BNP is released from the heart and is elevated in heart failure 
(HF), the relation between LV ejection fraction (EF) and diameter (LVIDd) and BNP lev- 
els have not been adequately described. Methods: Val-HeFT (Valsartan Heart Failure 
Trial) was a randomized, double-blind, placebo-controlled trial in 5,010 pts on precribed 
therapy for HF. Plasma BNP was measured by IRMA in 2 core labs at baseline and dur- 
mg follow-up. Echocardiographic examinations were performed and read in individual 
centers. with centralized QC. At baseline, 4,300 pts were divided by quartiles (a) of EF or 
LVIDd. 3,696 pts had paired measurements of BNP. EF and LVlDd at baseline and 4 
months. Results: At baseline, BNP was significantly higher in pts with depressed EF 
(246+9 pg/mL for pts in Ql vs. 122+3 pg/mL in Q4). BNP was also higher in pts with LV 
dilation (119i5 pg/mL for pts in Ql vs. 256+9 pg/mL in Q4). *-month changes in BNP 
were similarly related to those in EF and LVIDd: pts with 25% increase in EF or > 0.5 cm 
decrease in LVlDd showed a median change in BNP of -12 and -13 pg/mL. a significantly 
greater decrease than in pts with less favorable changes in EF (-5 pg/mL, p= 0.0002) and 
LVlDd (-5 pglmL, p= 0.0004). Conclusion: Baseline BNP is a marker of altered baseline 
LV structure and function in HF. Changes in BNP at 4 months from baseline reflect those 
of EF and LVIDd. 
PCI without excess mortality. 
Health Outcomes by Treatment 
MED PCI CABG 
Angina (%) 
Health Utility (l-100) 
Physical Function (mean) 
Baseline 49 
1 -year 26 
Baseline 61 
1 -year 63 
Baseline 44 
1 -year 51 
47 47 
23 13 
65 62 
67 70 
54 56 
54 65 
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888-l Obesity Influences the Accuracy of B-Type Natriuretic 
Peptide Measurement in Chronic Heart Failure 
Mandeep Ft. Mehra. Patricia A. Uber, Pablo F. Nasca, Bobbette C. Harris, Myung H 
Park, Robert L. Scott, Ochsner Clinic Foundation, New Orleans, LA 
Background: Since adipose cells express clearance receptors for natriuretic peptides, 
we evaluated the influence of obesity in measurement of b-type natriuretic peptide (BNP) 
levels in systolic heart failure (HF). 
Methods and Results: We studied 237 consecutive patients (age 56 * 13 years, 63% 
men and 50% African American) with chronic systolic HF (LVEF 24 * 10 %) optimally 
treated with neurohormonal blockade (91% ACEI or ARB and 75% beta blockers). Step- 
wise regression modeling was used to assess the relationship of body mass index (BMI) 
and BNP levels while controlling for demographic variables (age, race and gender), 
structural indices (LVEF and end diastolic diameter), severity of heart failure (NYHA 
class, lean body mass corrected peak VO,), and creatinine. The mean BMI was 29.3 f 
6.4 kg/m2 and 120 patients (51%) were obese with a BMI > 30 kg/m2. Despite similar 
functIonal class, LVEF, lean VC$, and renal function, BNP levels were significantly lower 
in obese subjects than non-obese. 
Group NYHA Class LVEF% LeanVO, SCr BNP (pg/ml) 
Non- 2.2 * 0.7 23 zt 9 23 * 9 1.3iO.7 402258 
Obese 
Obese 2.1 * 0.6 24210 23 * 5 1.320.4 263*23 
pvatue ns “s “s ns 0.009 
(Lean VO, in cclkglmin, Serum creatmine in mg/dl) 
Stepwise regression identified lower BMI. lower LVEF, worse NYHA class, African Amer- 
ican race and age as independent predictors of higher BNP levels. 
Conclusions: This investigation estabkshes obesity as an independent modifier of BNP 
levels I” chrome systolic HF. Thus, these findings not only point to obesity as a regulator 
of endogenous natriuretic peptides in HF but also imply that lower natriuretic peptide lev- 
els might suggest worse severity of HF in the obese. 
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888-3 Prevalence and Clinical Characteristics of Patients With 
Chronic Systolic Heart Failure and Normal Plasma 
Levels of B-Type Natriuretic Peptide 
W.H. Wilson Tang, John P. Girod, Michael J. Lee, Randall C. Starling, James B. Young, 
Gary S. Francis, The Cleveland Clinic Foundation, Cleveland, OH 
Backgrountt Despite the high negative predictive value of plasma B-type natriuretic 
peptide (BNP) in excluding a cardiac source of dyspnea. some patients with established 
chronic systolic heart failure have low plasma levels of BNP. We examine the prevalence 
and clinical characteristics of this patient cohort in a ‘“real world” practice setting. Meth- 
ods: We followed 269 consecutive patients with chronic systolic heari failure (LVEF 
c40%, NYHA II-IV, 51% ischemic) seen at the Cleveland Clinic outpatient heart failure 
clinic between 1 l/01 -6102. Retrospective chart review was performed to determine clini- 
cal, functional and echocardiographic data. Plasma BNP levels were determined by the 
Biosite Triage BNP assay with a standard cut-off point of 100 pg/mL. Clinical characteris- 
tics between patients with plasma BNP cl00 pg/mL and those ~100 pg/mL were com- 
pared usina univariate analvses.Resultr 54 oatients (19 %) have “normal” olasma BNP 
levels cl00 pg/mL, among them 31 (57%) had BNP = 50 pg/mL. Compared to those with 
BNP =lOO oo/mL. oatients with “normalll BNP levels were vounoer and more likelv to ._ I  _  
have non-ischemic etiology (79% vs 35%, p<O.OOl). They had higher LV ejection fraction 
(LVEF 29% vs 23%, p<O.OOl), lower LV end-diastolic dimension (LVIDd 58mm vs 62mm, 
p=O.OOS), and less comorbidities (atrial fibrillation 27% vs 60%, renal dysfunction 14% vs 
49%, p<O.OOl). However, age, gender, history of hypertension, presence of diastolic dys- 
function, and treatment patterns were similar between the two groups. Overall. plasma 
BNP levels were lower in patients with non-ischemic versus ischemic etiology (338 +I86 
vs 527 +181 oa/mL. ocO.oOll. even after adiustments for aae. sender. LVEF. LVIDd. ._ - _ 
renal function, and NYHA class.Conclusion: Up to one-fifth of patients with chronic sys- 
tolic heart failure demonstrate olasma BNP levels below 100 oo/mL. Althouoh lower BNP 
levels correlated with less cardiac remodeling and less comorbid conditions (as 
expected), non-ischemic cardiomyopathy predominates in this “normal” BNP cohort. It is 
conceivable that the heterogeneity of BNP expression and elimination may affect the 
interpretation of plasma BNP levels in patients with chronic systolic heart failure. 
